TOKYO, JAPAN: Nakashima Holdings Co Ltd and Teijin Limited announced that Teijin will acquire, through a third-party allotment, new shares of Nakashima Medical Co, Ltd, Nakashima Holdings’ wholly owned subsidiary specializing in joint prostheses, to establish a 50-50 joint venture named Teijin Nakashima Medical Co, Ltd as of 1 April 2015.
This tie-up will develop global business in the medical device field by integrating Nakashima’s core competencies in high-level metalworking and joint prostheses with Teijin’s expertise in materials technology, primarily polymeric chemistry, and healthcare-related development and sales capabilities.
The joint venture will strategically restructure its existing sales force in line with business targets that will be identified in cooperation with Teijin Pharma, a Teijin group company specialized in healthcare business. The new company aims to develop revolutionary products based on synergies between its two parent companies and incorporate a range of technologies, both internal and external, through Teijin’s global network.
Teijin Nakashima Medical will aim to become a major manufacturer of Japanese-made joint prostheses while laying the groundwork for global expansion.
© Worldofchemicals News